{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:26:47Z","timestamp":1793158007107,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-025-00274-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:03:37Z","timestamp":1762383817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs"],"prefix":"10.1186","volume":"9","author":[{"given":"Laura","family":"Alonzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Benfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Purpura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Galia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Brancatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Midiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-1640","authenticated-orcid":false,"given":"Pierpaolo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s12149-014-0856-3","volume":"28","author":"O Alonso","year":"2014","unstructured":"Alonso, O, Rodr\u00edguez-Taroco, M, Savio, E, Bentancourt, C, Gambini, JP, Engler, H (2014) 68Ga-DOTATATE PET\/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann Nucl Med 28:638\u2013645. https:\/\/doi.org\/10.1007\/s12149-014-0856-3","journal-title":"Ann Nucl Med"},{"key":"274_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s00259-012-2146-4","volume":"39","author":"V Ambrosini","year":"2012","unstructured":"Ambrosini, V, Campana, D, Nanni, C, Cambioli, S, Tomassetti, P, Rubello, D et al (2012) Is 68Ga-DOTA-NOC PET\/CT indicated in patients with clinical, Biochemical or radiological suspicion of neuroendocrine tumour? Eur J Nucl Med Mol Imag 39:1278\u20131283. https:\/\/doi.org\/10.1007\/s00259-012-2146-4","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"274_CR3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00259-023-06200-9","volume":"50","author":"D Chen","year":"2023","unstructured":"Chen, D, Yang, S, Chen, J, Li, T, Liu, Y, Zhao, X et al (2023) Comparison of [18F]-OC PET\/CT and contrast-enhanced CT\/MRI in the detection and evaluation of neuroendocrine neoplasms. Eur J Nucl Med Mol Imag 50:2420\u20132431. https:\/\/doi.org\/10.1007\/s00259-023-06200-9","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jfma.2017.07.007","volume":"117","author":"S-H Chen","year":"2018","unstructured":"Chen, S-H, Chang, Y-C, Hwang, T-L, Chen, J-S, Chou, W-C, Hsieh, C-H et al (2018) 68Ga-DOTATOC and 18F-FDG PET\/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: a prospective study in Taiwan. J Formos Med Assoc 117:480\u2013487. https:\/\/doi.org\/10.1016\/j.jfma.2017.07.007","journal-title":"J Formos Med Assoc"},{"key":"274_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.2967\/jnumed.114.144543","volume":"55","author":"Etchebehere ECS de C","year":"2014","unstructured":"de C, Etchebehere ECS, de Oliveira Santos A, Gumz, B, Vicente, A, Hoff, PG, Corradi, G et al (2014) 68 Ga-DOTATATE PET\/CT, 99m Tc-HYNIC-Octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 55:1598\u20131604. https:\/\/doi.org\/10.2967\/jnumed.114.144543","journal-title":"J Nucl Med"},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/diagnostics11020334","volume":"11","author":"MF Froelich","year":"2021","unstructured":"Froelich, MF, Schnitzer, ML, Holzgreve, A, Gassert, FG, Gresser, E, Overhoff, D et al (2021) Cost-effectiveness analysis of 68Ga DOTA-TATE PET\/CT, 111In-pentetreotide SPECT\/CT and CT for diagnostic workup of neuroendocrine tumors. Diagnostics 11:334. https:\/\/doi.org\/10.3390\/diagnostics11020334","journal-title":"Diagnostics"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MNM.0000000000000623","volume":"38","author":"M Haidar","year":"2017","unstructured":"Haidar, M, Shamseddine, A, Panagiotidis, E, Jreige, M, Mukherji, D, Assi, R et al (2017) The role of 68Ga-DOTA-NOC PET\/CT in evaluating neuroendocrine tumors. Nucl Med Commun 38:170\u2013177. https:\/\/doi.org\/10.1097\/MNM.0000000000000623","journal-title":"Nucl Med Commun"},{"key":"274_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","volume":"53","author":"AR Haug","year":"2012","unstructured":"Haug, AR, Cindea-Drimus, R, Auernhammer, CJ, Reincke, M, W\u00e4ngler, B, Uebleis, C et al (2012) The role of 68 Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors. J Nucl Med 53:1686\u20131692. https:\/\/doi.org\/10.2967\/jnumed.111.101675","journal-title":"J Nucl Med"},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope, TA, Allen-Auerbach, M, Bodei, L, Calais, J, Dahlbom, M, Dunnwald, LK et al (2023) SNMMI Procedure Standard\/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med 64:204\u2013210. https:\/\/doi.org\/10.2967\/jnumed.122.264860","journal-title":"J Nucl Med"},{"key":"274_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.113.126896","volume":"55","author":"A Imperiale","year":"2014","unstructured":"Imperiale, A, Rust, E, Gabriel, S, Detour, J, Goichot, B, Duclos, B et al (2014) 18 F-Fluorodihydroxyphenylalanine PET\/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med 55:367\u2013372. https:\/\/doi.org\/10.2967\/jnumed.113.126896","journal-title":"J Nucl Med"},{"key":"274_CR11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1007\/s00330-016-4475-3","volume":"27","author":"PM Kazmierczak","year":"2017","unstructured":"Kazmierczak, PM, Rominger, A, Wenter, V, Spitzweg, C, Auernhammer, C, Angele, MK et al (2017) The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Eur Radiol 27:1676\u20131684. https:\/\/doi.org\/10.1007\/s00330-016-4475-3","journal-title":"Eur Radiol"},{"key":"274_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1196\/annals.1294.002","volume":"1014","author":"G Kl\u00f6ppel","year":"2004","unstructured":"Kl\u00f6ppel, G, Perren, A, Heitz, PU (2004) The Gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13\u201327. https:\/\/doi.org\/10.1196\/annals.1294.002","journal-title":"Ann N Y Acad Sci"},{"key":"274_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","volume":"13","author":"Y Krausz","year":"2011","unstructured":"Krausz, Y, Freedman, N, Rubinstein, R, Lavie, E, Orevi, M, Tshori, S et al (2011) 68Ga-DOTA-NOC PET\/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-Octreotide (OctreoScan\u00ae). Mol Imaging Biol 13:583\u2013593. https:\/\/doi.org\/10.1007\/s11307-010-0374-1","journal-title":"Mol Imaging Biol"},{"key":"274_CR14","doi-asserted-by":"publisher","first-page":"e23210","DOI":"10.1097\/MD.0000000000023210","volume":"99","author":"Y Li","year":"2020","unstructured":"Li, Y, Li, F, Li, X, Qu, L, Han, J (2020) Value of 18F-FDG PET\/CT in patients with hepatic metastatic carcinoma of unknown primary. Medicine (baltimore) 99:e23210. https:\/\/doi.org\/10.1097\/MD.0000000000023210","journal-title":"Medicine (baltimore)"},{"key":"274_CR15","unstructured":"Lloyd, RV, Osamura RY, Kl\u00f6ppel G, Rosai J Ricardo, V. Lloyd, Robert, Y. Osamura, G Kl\u00f6ppel, Juan Rosai (2017) WHO for R on cancer. WHO classification of tumours of endocrine organs. International Agency for Research on Cancer IARC, Lyon, France. 1940"},{"key":"274_CR16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2967\/jnumed.116.180984","volume":"58","author":"Y Menda","year":"2017","unstructured":"Menda, Y, O\u2019Dorisio, TM, Howe, JR, Schultz, M, Dillon, JS, Dick, D et al (2017) Localization of unknown primary site with 68 Ga-DOTATOC PET\/CT in patients with metastatic neuroendocrine tumor. J Nucl Med 58:1054\u20131057. https:\/\/doi.org\/10.2967\/jnumed.116.180984","journal-title":"J Nucl Med"},{"key":"274_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2214\/AJR.11.7298","volume":"197","author":"N Naswa","year":"2011","unstructured":"Naswa, N, Sharma, P, Kumar, A, Nazar, AH, Kumar, R, Chumber, S et al (2011) Gallium-68-DOTA-NOC PET\/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Am J Roentgenol 197:1221\u20131228. https:\/\/doi.org\/10.2214\/AJR.11.7298","journal-title":"Am J Roentgenol"},{"key":"274_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6061\/clinics\/2012(Sup01)18","volume":"67","author":"K \u00d6berg","year":"2012","unstructured":"\u00d6berg, K (2012) Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics 67:109\u2013112. https:\/\/doi.org\/10.6061\/clinics\/2012(Sup01)18","journal-title":"Clinics"},{"key":"274_CR19","doi-asserted-by":"publisher","unstructured":"Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD et al (2021) The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"274_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad, V, Ambrosini, V, Hommann, M, Hoersch, D, Fanti, S, Baum, RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imag 37:67\u201377. https:\/\/doi.org\/10.1007\/s00259-009-1205-y","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"274_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.21037\/jgo.2016.01.06","volume":"7","author":"A Pruthi","year":"2016","unstructured":"Pruthi, A, Pankaj, P, Verma, R, Jain, A, Belho, ES, Mahajan, H (2016) Ga-68 DOTANOC PET\/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J Gastrointest Oncol 7:449\u2013461. https:\/\/doi.org\/10.21037\/jgo.2016.01.06","journal-title":"J Gastrointest Oncol"},{"key":"274_CR22","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi, G, Klimstra, DS, Abedi-Ardekani, B, Asa, SL, Bosman, FT, Brambilla, E et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology 31:1770\u20131786. https:\/\/doi.org\/10.1038\/s41379-018-0110-y","journal-title":"Modern Pathology"},{"key":"274_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski, SM, Neychev, V, Millo, C, Shih, J, Nilubol, N, Herscovitch, P et al (2016) Prospective study of 68 Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 34:588\u2013596. https:\/\/doi.org\/10.1200\/JCO.2015.64.0987","journal-title":"J Clin Oncol"},{"key":"274_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2967\/jnmt.116.185777","volume":"45","author":"N Sampathirao","year":"2017","unstructured":"Sampathirao, N, Basu, S (2017) MIB-1 index-stratified assessment of dual-tracer PET\/CT with 68 Ga-DOTATATE and 18 F-FDG and Multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. J Nucl Med Technol 45:34\u201341. https:\/\/doi.org\/10.2967\/jnmt.116.185777","journal-title":"J Nucl Med Technol"},{"key":"274_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2478\/raon-2014-0018","volume":"48","author":"NF Schreiter","year":"2014","unstructured":"Schreiter, NF, Bartels, A-M, Froeling, V, Steffen, I, Pape, U-F, Beck, A et al (2014) Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET\/CT and In-111 DTPA octreotide SPECT\/CT. Radiol Oncol 48:339\u2013347. https:\/\/doi.org\/10.2478\/raon-2014-0018","journal-title":"Radiol Oncol"},{"key":"274_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/RLU.0000000000000257","volume":"39","author":"P Sharma","year":"2014","unstructured":"Sharma, P, Arora, S, Mukherjee, A, Pal, S, Sahni, P, Garg, P et al (2014) Predictive value of 68Ga-DOTANOC PET\/CT in patients with suspicion of neuroendocrine tumors. Clin Nucl Med 39:37\u201343. https:\/\/doi.org\/10.1097\/RLU.0000000000000257","journal-title":"Clin Nucl Med"},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/0976-500X.107697","volume":"4","author":"J Singh","year":"2013","unstructured":"Singh, J (2013) Critical appraisal skills programme. J Pharmacol Pharmacother 4:76\u201377. https:\/\/doi.org\/10.4103\/0976-500X.107697","journal-title":"J Pharmacol Pharmacother"},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin, A, Arnold, R, Baudin, E, Cwikla, JB, Eriksson, B, Fanti, S et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 105:212\u2013244. https:\/\/doi.org\/10.1159\/000471879","journal-title":"Neuroendocrinology"},{"key":"274_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/RLU.0000000000004963","volume":"49","author":"C Sung","year":"2024","unstructured":"Sung, C, Lee, HS, Lee, DY, Kim, Y, Kim, JE, Lee, SJ et al (2024) A prospective comparative study of 18F-FDOPA PET\/CT versus 123I-MIBG scintigraphy with SPECT\/CT for the diagnosis of pheochromocytoma and Paraganglioma. Clin Nucl Med 49:27\u201336. https:\/\/doi.org\/10.1097\/RLU.0000000000004963","journal-title":"Clin Nucl Med"},{"key":"274_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s13139-013-0258-9","volume":"48","author":"TH Tan","year":"2014","unstructured":"Tan, TH, Lee, BN, Hassan, SZA (2014) Diagnostic value of 68Ga-DOTATATE PET\/CT in liver metastases of neuroendocrine tumours of unknown origin. Nucl Med Mol Imaging 48:212\u2013215. https:\/\/doi.org\/10.1007\/s13139-013-0258-9","journal-title":"Nucl Med Mol Imaging"},{"key":"274_CR31","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, JC, Hassan, M, Phan, A, Dagohoy, C, Leary, C, Mares, JE et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 26:3063\u20133072. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377","journal-title":"J Clin Oncol"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-025-00274-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T23:03:38Z","timestamp":1762383818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-025-00274-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1186\/s41824-025-00274-4","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article; therefore, ethical approval is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The other authors declare no conficts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}